PBPK model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathways (Q39247285)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	PBPK model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathways	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

PBPK model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathways (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

author name string

M D L T Vieira

1

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

M-J Kim

2

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

S Apparaju

3

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

V Sinha

4

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

I Zineh

5

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

S-M Huang

6

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

P Zhao

7

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

language of work or name

0 references

publication date

20 February 2014

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Clinical Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

95

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

550-557

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

The utility of modeling and simulation in drug development and regulatory review

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

BDDCS applied to over 900 drugs

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Pharmacokinetic drug interactions with cyclosporin (Part I).

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Macrolide-induced digoxin toxicity: a population-based study.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Pharmacokinetic and Pharmacodynamic Interactions of Oral Midazolam with Ketoconazole, Fluoxetine, Fluvoxamine, and Nefazodone

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Comparison of In Vitro and In Vivo Inhibition Potencies of Fluvoxamine toward CYP2C19

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Clinical pharmacokinetics of fluoxetine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

21 January 2018

Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of the Pharmacokinetic and Pharmacodynamic Interaction Between Quinidine and Nifedipine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.43

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/CLPT.2014.43

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39247285&oldid=1815873492"